Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Duchenne UK
London, England, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Duchenne UK funds and accelerates translational research in Duchenne muscular dystrophy, aiming to bring gene therapies, cell therapies, and new small molecules like vamorolone to market; contributed to research and recent UK approval of vamorolone for DMD.
- Therapeutic areas
- Rare Diseases
- Modalities
- Gene therapyCell therapySmall moleculeBiologicEnzyme replacement therapyRNA therapySteroid
- Industry
- Investors
02
Partnerships
Parent Project Muscular DystrophyJohn Walton Muscular Dystrophy Research CentreFoodbuy
Beyond the preview
Go deeper on Duchenne UK.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duchenne UK.